ArcticZymes | GenomeWeb

ArcticZymes

As part of the effort, Virus.X also aims to craft new sequencing approaches, bioinformatics tools, and targeted gene products.

The Biotec Pharmacon subsidiary is taking part in the Virus-X EU Consortium by developing new viral enzymes and bringing them to the market.

ArcticZymes said last week that it has inked a supply agreement with GE Healthcare Life Sciences for products based on ArcticZymes' portfolio of heat-labile enzymes.

ArcticZymes and New England Biolabs have signed a supply agreement for ArcticZymes' recombinant shrimp alkaline phosphatase, or SAP, enzyme.

By Ben Butkus
ArcticZymes, a Norwegian life science research tools firm specializing in cold-adapted and heat-labile enzymes for use in molecular biology and diagnostics, this week opened its first US office in the outskirts of Philadelphia.

ArcticZymes has named Brent Spoth as business development manager for the Americas.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Biotec Pharmacon today announced it has reached a new non-exclusive deal with Affymetrix for the distribution of ArcticZymes' shrimp alkaline phosphatase (SAP).

TATAA will sell ArcticZymes' heat-labile enzymes for use in contamination control through its sales channels; and will integrate ArcticZymes' products into its range of courses.

The companies will sell each other's products in Europe.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.